O’Malley Reviews Standard Therapies for Patients with Platinum-Agnostic Ovarian Cancer
David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
David M. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
According to O’Malley, there is a growing group of patients who are not eligible to platinum therapy due to either hypersensitive or treatment with the agent in the past. These patients are often no longer eligible for clinical trials.
When looking at this population group, the overall historical experience of this group is limited. This means that data on this population is equally limited, according to O’Malley. Patients who are platinum-agnostic are often treated with non-platinum containing agents, such as bevacizumab (Avastin).
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
